PL2421849T3 - Związki diamidowe wykazujące aktywność antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta2 - Google Patents

Związki diamidowe wykazujące aktywność antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta2

Info

Publication number
PL2421849T3
PL2421849T3 PL10715058T PL10715058T PL2421849T3 PL 2421849 T3 PL2421849 T3 PL 2421849T3 PL 10715058 T PL10715058 T PL 10715058T PL 10715058 T PL10715058 T PL 10715058T PL 2421849 T3 PL2421849 T3 PL 2421849T3
Authority
PL
Poland
Prior art keywords
agonist activity
diamide compounds
beta2 adrenergic
receptor antagonist
receptor agonist
Prior art date
Application number
PL10715058T
Other languages
English (en)
Inventor
Adam Hughes
Daniel Byun
Yan Chen
Melissa Fleury
John R Jacobsen
Eric L Stangeland
Richard D Wilson
Rose Yen
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2421849(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of PL2421849T3 publication Critical patent/PL2421849T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL10715058T 2009-04-23 2010-04-16 Związki diamidowe wykazujące aktywność antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta2 PL2421849T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17203909P 2009-04-23 2009-04-23
EP10715058A EP2421849B1 (en) 2009-04-23 2010-04-16 Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
PCT/US2010/031356 WO2010123766A1 (en) 2009-04-23 2010-04-16 DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Publications (1)

Publication Number Publication Date
PL2421849T3 true PL2421849T3 (pl) 2013-08-30

Family

ID=42272140

Family Applications (3)

Application Number Title Priority Date Filing Date
PL17164740T PL3210981T3 (pl) 2009-04-23 2010-04-16 Związki diamidowe wykazujące działanie jako antagonista receptora muskarynowego i agonista antagonista receptora beta 2 adrenergicznego
PL10715058T PL2421849T3 (pl) 2009-04-23 2010-04-16 Związki diamidowe wykazujące aktywność antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta2
PL13151470T PL2599778T3 (pl) 2009-04-23 2010-04-16 Związki diamidowe mających działanie antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta 2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17164740T PL3210981T3 (pl) 2009-04-23 2010-04-16 Związki diamidowe wykazujące działanie jako antagonista receptora muskarynowego i agonista antagonista receptora beta 2 adrenergicznego

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13151470T PL2599778T3 (pl) 2009-04-23 2010-04-16 Związki diamidowe mających działanie antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta 2

Country Status (31)

Country Link
US (14) US8138345B2 (pl)
EP (3) EP3210981B1 (pl)
JP (3) JP5671006B2 (pl)
KR (1) KR101769061B1 (pl)
CN (2) CN102405218B (pl)
AR (1) AR076412A1 (pl)
AU (1) AU2010239522B2 (pl)
BR (1) BRPI1014877B8 (pl)
CA (1) CA2758505C (pl)
CL (1) CL2011002637A1 (pl)
CO (1) CO6440584A2 (pl)
CY (2) CY1119008T1 (pl)
DK (3) DK2599778T3 (pl)
ES (3) ES2635358T3 (pl)
HR (3) HRP20130468T1 (pl)
HU (2) HUE042975T2 (pl)
IL (1) IL215554A (pl)
LT (2) LT3210981T (pl)
MX (1) MX2011011156A (pl)
MY (1) MY158339A (pl)
NZ (1) NZ595850A (pl)
PL (3) PL3210981T3 (pl)
PT (3) PT2599778T (pl)
RU (2) RU2676686C2 (pl)
SG (1) SG175330A1 (pl)
SI (3) SI2421849T1 (pl)
SM (3) SMT201900168T1 (pl)
TR (1) TR201903556T4 (pl)
TW (2) TWI513693B (pl)
WO (1) WO2010123766A1 (pl)
ZA (1) ZA201107743B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2635358T3 (es) 2009-04-23 2017-10-03 Theravance Respiratory Company, Llc Compuestos de diamina que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
AR083115A1 (es) * 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
BR112013031493B1 (pt) 2011-06-10 2022-04-19 Chiesi Farmaceutici S.P.A Composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto
KR20180085068A (ko) 2011-06-10 2018-07-25 키에시 파르마슈티시 엣스. 피. 에이. 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
SG10201704032RA (en) 2012-12-06 2017-06-29 Chiesi Farm Spa Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN104854105B (zh) 2012-12-06 2017-05-17 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
ES2750523T3 (es) 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
CN104030933A (zh) * 2014-05-16 2014-09-10 烟台恒迪克能源科技有限公司 一种β-异烷醇基氨基戊酸环己胺的合成方法
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β2腎上腺素受體促效劑活性之化合物
WO2016155573A1 (zh) * 2015-03-27 2016-10-06 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
CN107108502A (zh) * 2015-05-14 2017-08-29 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的联苯衍生物及其在医药上的用途
WO2016180348A1 (zh) * 2015-05-14 2016-11-17 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的含氮杂螺环衍生物及其在医药上的用途
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2017125060A1 (zh) * 2016-01-22 2017-07-27 四川海思科制药有限公司 一种氮杂环酰胺衍生物及其制备方法和在医药上的用途
WO2018011090A1 (en) 2016-07-13 2018-01-18 Chiesi Farmaceutici S.P.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
KR102278197B1 (ko) 2016-12-14 2021-07-15 베이징 서우바이 파마슈티컬 컴퍼니 리미티드 4차 암모늄염 구조의 이중기능 화합물
WO2018211530A1 (en) 2017-05-19 2018-11-22 Council Of Scientific & Industrial Research Substituted methanopyrido [2, 1-a] isoindolonesas machr modulators for treating various associated pathophysiological conditions and process for preparation thereof
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
US10562930B1 (en) * 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
CN117924216A (zh) * 2024-01-12 2024-04-26 王叔和生物医药(武汉)有限公司 一种1-哌啶丙酸的合成方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
ATE299494T1 (de) 1999-12-07 2005-07-15 Theravance Inc Carbamat-derivate als muscarin-rezeptor antonisten
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
CA2417826A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
CN1255012C (zh) * 2001-12-04 2006-05-03 东京研发股份有限公司 供电装置
CN101239971B (zh) * 2003-02-14 2011-07-20 施万制药 联苯衍生物
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
ME00557A (en) 2004-01-22 2011-12-20 Sulfonamide derivatives for the treatment of diseases
WO2005080375A1 (en) * 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7307076B2 (en) 2004-05-13 2007-12-11 Boehringer Ingelheim International Gmbh Beta agonists for the treatment of respiratory diseases
JP2008510015A (ja) * 2004-08-16 2008-04-03 セラヴァンス, インコーポレーテッド β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
JP2008510014A (ja) * 2004-08-16 2008-04-03 セラヴァンス, インコーポレーテッド β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
CA2641706C (en) 2006-02-08 2014-12-23 Fuji Oil Company, Limited Edible products with low content of saturated and trans unsaturated fats
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
WO2010011314A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
ES2635358T3 (es) 2009-04-23 2017-10-03 Theravance Respiratory Company, Llc Compuestos de diamina que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico

Also Published As

Publication number Publication date
US8138345B2 (en) 2012-03-20
BRPI1014877B1 (pt) 2020-11-10
TWI570115B (zh) 2017-02-11
SMT201300060B (it) 2013-07-09
BRPI1014877A2 (pt) 2016-04-12
US10358433B2 (en) 2019-07-23
RU2011147374A (ru) 2013-05-27
US20210024493A1 (en) 2021-01-28
CN102405218A (zh) 2012-04-04
HUE035049T2 (en) 2018-05-02
US10836744B2 (en) 2020-11-17
CN102405218B (zh) 2014-06-04
US20150274697A1 (en) 2015-10-01
MY158339A (en) 2016-09-30
EP2421849B1 (en) 2013-04-03
HRP20190417T1 (hr) 2019-04-19
JP2012524783A (ja) 2012-10-18
AU2010239522B2 (en) 2015-07-02
SI2599778T1 (sl) 2017-08-31
RU2676686C2 (ru) 2019-01-10
PT2421849E (pt) 2013-05-27
EP2599778A1 (en) 2013-06-05
PL2599778T3 (pl) 2018-01-31
JP2015147807A (ja) 2015-08-20
PT3210981T (pt) 2019-04-01
US8551978B2 (en) 2013-10-08
KR20110138292A (ko) 2011-12-26
HK1165799A1 (en) 2012-10-12
IL215554A (en) 2014-08-31
LT3210981T (lt) 2019-04-10
ES2417339T3 (es) 2013-08-07
US20170096412A1 (en) 2017-04-06
TW201546057A (zh) 2015-12-16
JP5671006B2 (ja) 2015-02-18
ZA201107743B (en) 2012-06-27
CA2758505C (en) 2017-03-07
EP3210981A1 (en) 2017-08-30
CN103936716A (zh) 2014-07-23
RU2015101032A3 (pl) 2018-07-30
MX2011011156A (es) 2011-11-04
US20170226082A1 (en) 2017-08-10
TR201903556T4 (tr) 2019-04-22
US20130137665A1 (en) 2013-05-30
EP2599778B1 (en) 2017-04-12
US10590107B2 (en) 2020-03-17
SG175330A1 (en) 2011-11-28
ES2635358T3 (es) 2017-10-03
US9975875B2 (en) 2018-05-22
ES2715965T3 (es) 2019-06-07
DK3210981T3 (en) 2019-04-01
TW201041866A (en) 2010-12-01
RU2015101032A (ru) 2015-06-27
EP3210981B1 (en) 2019-01-02
HUE042975T2 (hu) 2019-07-29
TWI513693B (zh) 2015-12-21
WO2010123766A1 (en) 2010-10-28
BRPI1014877B8 (pt) 2021-05-25
CL2011002637A1 (es) 2012-04-27
US9682957B2 (en) 2017-06-20
AR076412A1 (es) 2011-06-08
US20200165223A1 (en) 2020-05-28
KR101769061B1 (ko) 2017-08-17
US20140323733A1 (en) 2014-10-30
JP2014210816A (ja) 2014-11-13
DK2599778T3 (en) 2017-06-26
US9394275B2 (en) 2016-07-19
US20170362200A1 (en) 2017-12-21
PT2599778T (pt) 2017-06-06
LT2599778T (lt) 2017-08-25
NZ595850A (en) 2013-05-31
HRP20170960T1 (hr) 2017-09-22
EP2421849A1 (en) 2012-02-29
CO6440584A2 (es) 2012-05-15
US9771350B2 (en) 2017-09-26
CA2758505A1 (en) 2010-10-28
IL215554A0 (en) 2011-12-29
US9000173B2 (en) 2015-04-07
CY1121601T1 (el) 2020-05-29
US20100273755A1 (en) 2010-10-28
BRPI1014877A8 (pt) 2018-03-13
US8816088B2 (en) 2014-08-26
US9572802B2 (en) 2017-02-21
DK2421849T3 (da) 2013-07-01
US20130331364A1 (en) 2013-12-12
CN103936716B (zh) 2016-09-07
US20160361304A1 (en) 2016-12-15
CY1119008T1 (el) 2018-01-10
SI3210981T1 (sl) 2019-05-31
AU2010239522A1 (en) 2011-11-10
SMT201900168T1 (it) 2019-05-10
SI2421849T1 (sl) 2013-07-31
JP5965440B2 (ja) 2016-08-03
US10138220B1 (en) 2018-11-27
PL3210981T3 (pl) 2019-06-28
US20190300504A1 (en) 2019-10-03
HRP20130468T1 (en) 2013-06-30
US20190047984A1 (en) 2019-02-14
SMT201700305T1 (it) 2017-09-07
RU2543716C2 (ru) 2015-03-10

Similar Documents

Publication Publication Date Title
IL215554A0 (en) Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
ZA201309242B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
PL2928890T3 (pl) Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych
ZA201503965B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
KR20180085068A (ko) 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
IL219893A0 (en) Combinations of a muscarinic receptor antagonist and a beta-2 adrenorecptor agonist
LT2569308T (lt) Naujieji cikloheksilamino dariniai, turintys beta2 adrenerginio agonisto ir m3 muskarininio antagonisto aktyvumus